Critical reagent considerations for immunogenicity assay development for bispecific biotherapeutic candidates.

导出 OA

翻译打印收藏纠错

作者： Arkadeep,Sinha ^[1] ; Sherri,Rinker ^[2] ; Mallory Rose,Souliotis ^[3] ; Rajesh,Kumar ^[4] ; Seema,Kumar ^[5] ; Kyra J,Cowan ^[6]

作者单位： Clinical Bioanalytical Sciences, EMD Serono Research & Development Institute, Inc., 45A Middlesex Turnpike, Billerica, MA 01821, USA.;Upstream Bio, 460 Totten Pond Rd. Suite 420, Waltham, MA 02451, USA. ^[1] B2S Life Sciences, 97 East Monroe Street, Franklin, IN 46131, USA. ^[2] Clinical Bioanalytical Sciences, EMD Serono Research & Development Institute, Inc., 45A Middlesex Turnpike, Billerica, MA 01821, USA.;Bioagilytix, 1320 Soldiers Field Rd, Boston, MA 02135, USA. ^[3] Clinical Bioanalytical Sciences, EMD Serono Research & Development Institute, Inc., 45A Middlesex Turnpike, Billerica, MA 01821, USA. ^[4] Clinical Bioanalytical Sciences, EMD Serono Research & Development Institute, Inc., 45A Middlesex Turnpike, Billerica, MA 01821, USA.;Pioneering Medicines at Flagship Pioneering, 140 First St, Cambridge, MA 02141, USA. ^[5] Merck Healthcare KGaA, Frankfurter Str. 250, Postcode D50/225, 64293, Darmstadt, Germany. ^[6]

关键词 LBA anti-drug antibody critical reagents immunoassay immunogenicity multi-specific antibodies

主题词人类(Humans);抗体, 双特异性(Antibodies, Bispecific);指示剂和试剂(Indicators and Reagents)

DOI 10.1080/17576180.2024.2366091

PMID 39023274

发布时间 2024-09-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交